Vir Biotechnology (VIR) Total Liabilities (2018 - 2026)

Vir Biotechnology's Total Liabilities history runs 9 years deep, the most recent figure standing at $212.8 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 19.36% year-over-year to $212.8 million; the TTM figure through Mar 2026 stood at $212.8 million (down 19.36% YoY), while the FY2025 annual figure was $237.5 million, down 4.38% from the prior year.
• Total Liabilities came in at $212.8 million for Q1 2026 at Vir Biotechnology, down from $237.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $886.1 million in Q1 2022 to a low of $212.8 million in Q1 2026.
• A 5-year average of $401.3 million and a median of $263.9 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 108.27% in 2022 and tumbled 64.52% in 2024, its largest moves.
• Vir Biotechnology's Total Liabilities stood at $724.1 million in 2022, then sank by 54.59% to $328.8 million in 2023, then decreased by 24.45% to $248.4 million in 2024, then dropped by 4.38% to $237.5 million in 2025, then slipped by 10.41% to $212.8 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $212.8 million, $237.5 million, and $223.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison